Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ME2 | P23368 | 13/20 | 0.49 |
| ▸ | ME1 | P48163 | 13/20 | 0.49 |
| ▸ | ME3 | Q16798 | 13/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15205402 | 0.84 | AKR1C3 (0.50) | ME2ME1ME3NPC1RAB9A | |
| SCHEMBL29521781 | 0.81 | ME2 (0.44) | ME2ME1ME3ESR2 | |
| SCHEMBL20475487 | 0.81 | ME2 (0.44) | ME2ME1ME3ESR2 | |
| SCHEMBL21551525 | 0.77 | ME2 (0.66) | ME2ME1ME3DRD4AKR1C3 | |
| SCHEMBL20475499 | 0.76 | DGAT1 (0.38) | NPC1RAB9AKMT2AOPRM1HSD11B1 | |
| SCHEMBL20956381 | 0.72 | TRPV1 (0.48) | OPRM1OPRD1OPRK1OGFRL1 | |
| SCHEMBL29576128 | 0.70 | ME2 (0.60) | ME2ME1ME3 | |
| SCHEMBL1977631 | 0.69 | LMNA (0.56) | ME2ME1ME3DEGS1KMT2A | |
| SCHEMBL17987101 | 0.68 | FYN (0.54) | ME2ME1ME3RAB9A | |
| SCHEMBL28956353 | 0.68 | ME2 (0.55) | ME2ME1ME3DRD4DEGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3582780-B1 | AMINO PYRIMIDINE COMPOUNDS USEFUL AS SSAO INHIBITORS | LILLY CO ELI (US) | 2021-10-13 | — | — | EP | disclosed |
| US-10471060-B2 | Amino pyrimidine compounds useful as SSAO inhibitors | ELI LILLY AND COMPANY (US) | 2019-11-12 | — | — | US | disclosed |
| US-20190275041-A1 | AMINO PYRIMIDINE COMPOUNDS USEFUL AS SSAO INHIBITORS | ELI LILLY AND COMPANY (US) | 2019-09-12 | — | — | US | disclosed |
| US-10278970-B2 | Amino pyrimidine compounds useful as SSAO inhibitors | ELI LILLY AND COMPANY (US) | 2019-05-07 | — | — | US | disclosed |
| US-20180296560-A1 | AMINO PYRIMIDINE COMPOUNDS USEFUL AS SSAO INHIBITORS | ELI LILLY AND COMPANY | 2018-10-18 | — | — | US | disclosed |
| WO-2018151985-A1 | AMINO PYRIMIDINE COMPOUNDS USEFUL AS SSAO INHIBITORS | ELI LILLY AND COMPANY (US) | 2018-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10278970-B2 | Amino pyrimidine compounds useful as SSAO inhibitors | DPYD, TYMP, NUDT1 | ME2 1907/4885ME1 2147/4885ME3 1683/4885 |
| US-20180296560-A1 | AMINO PYRIMIDINE COMPOUNDS USEFUL AS SSAO INHIBITORS | DPYD, TYMP, NUDT1 | ME2 1907/4885ME1 2147/4885ME3 1683/4885 |
| US-10471060-B2 | Amino pyrimidine compounds useful as SSAO inhibitors | DPYD, TYMP, NUDT1 | ME2 1907/4885ME1 2147/4885ME3 1683/4885 |
| US-20190275041-A1 | AMINO PYRIMIDINE COMPOUNDS USEFUL AS SSAO INHIBITORS | DPYD, TYMP, NUDT1 | ME2 1907/4885ME1 2147/4885ME3 1683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.